Research programme: I-kappa B kinase inhibitors - Millennium/sanofi-aventis

Drug Profile

Research programme: I-kappa B kinase inhibitors - Millennium/sanofi-aventis

Alternative Names: MLN 120B; PS 1145

Latest Information Update: 19 Mar 2012

Price : $50

At a glance

  • Originator Millennium Pharmaceuticals
  • Developer Millennium; Sanofi; sanofi-aventis
  • Class
  • Mechanism of Action I-kappa B kinase inhibitors; NF-kappa B inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No

Highest Development Phases

  • Discontinued Cancer; Chronic obstructive pulmonary disease; Inflammation; Multiple sclerosis; Rheumatoid arthritis

Most Recent Events

  • 18 Mar 2009 Discontinued - Preclinical for Multiple sclerosis in USA (unspecified route)
  • 18 Mar 2009 Discontinued - Preclinical for Inflammation in USA (PO)
  • 18 Mar 2009 Discontinued - Preclinical for Chronic obstructive pulmonary disease in USA (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top